|
[1]SI CW.Current status and problem of chronic hepatitis B[J].Clin Med J,2006,4(4):1-2.(in Chinese)斯崇文.慢性乙型肝炎的现状和问题[J].临床药物治疗杂志,2006,4(4):1-2.
|
|
[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[3]SU TH,KAO JH.Improving clinical outcomes of chronic hepatitis B virus infection[J].Expert Rev Gastroenterol Hepatol,2015,9(2):141-154.
|
|
[4]PETERSEN J,DANDRI M.Optimal therapy for chronic hepatitis B:hepatitis B virus combination therapy?[J].Liver Int,2015,35(Suppl 1):114-120.
|
|
[5]LIN CL,KAO JH.Review article:novel therapies for hepatitis B virus cure-advances and perspectives[J].Aliment Pharmacol Ther,2016,44(3):213-222.
|
|
[6]YAPALI S,TALAAT N,LOK AS.Management of hepatitis B:our practice and how it relates to the guidelines[J].Clin Gastroenterol Hepatol,2014,12(1):16-26.
|
|
[7]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B[J].J Hepatol,2009,50(2):227-242.
|
|
[8]ALLWEISS L,VOLZ T,LUTGEHETMANN M,et al.Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration[J].J Hepatol,2014,60(3):500-507.
|
|
[9]MARCELLIN P,AHN SH,MA X,et al.Combination of tenofovir disoproxil fumarate and peginterferonα-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J].Gastroenterology,2016,150(1):134-144.e10.
|
|
[10]MARCELLIN P,LAU GK,BONINO F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeA g-negative chronic hepatitis B[J].N Engl J Med,2004,351(12):1206-1217.
|
|
[11]LAU GKK,PIRATVISUTH T,LUO KX,et al.Peginterferon alfa-2a,lamivudine,and the combination for HBeA g-positive chronic hepatitis B[J].N Engl J Med,2005,352(26):2682-2695.
|
|
[12]JANSSEN HL,van ZONNEVELD M,SENTURK H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeA g-positive chronic hepatitis B:a randomised trial[J].Lancet,2005,365(9454):123-129.
|
|
[13]TAKKENBERG RB,JANSEN L,de NIET A,et al.Baseline hepatitis B surface antigen(HBs Ag)as predictor of sustained HBs Ag loss in chronic hepatitis B patients treated with Pegylated interferon-alpha2a and adefovir[J].Antivir Ther,2013,18(7):895-904.
|
|
[14]XIE Q,ZHOU H,BAI X,et al.A randomized,open-label clinical study of combined Pegylated interferon alfa-2a(40KD)and entecavir treatment for hepatitis B“e”antigenpositive chronic hepatitis B[J].Clin Infect Dis,2014,59(12):1714-1723.
|
|
[15]PICCOLO P,LENCI I,DEMELIA L,et al.A randomized controlled trial of Pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B[J].Antivir Ther,2009,14(8):1165-1174.
|
|
[16]FAN R,SUN J,HOU JL.Combination therapy with tenofovir and Peginterferon may not be translated into current clinical practice[J].Gastroenterology,2016,150(5):1253-1254.
|
|
[17]BROUWER WP,XIE Q,SONNEVELD MJ,et al.Adding Pegylated interferon to entecavir for hepatitis B e antigenpositive chronic hepatitis B:a multicenter randomized trial(ARES study)[J].Hepatology,2015,61(5):1512-1522.
|
|
[18]HENG C,XIE Q,ZHANG NP,et al.Addition of peginterferon alfa-2b during long-term nucleos(t)ide analogue therapy increases HBeA g seroconversion and HBsA g decline-week 48results from a multicenter randomized controlled trial[C].AASLD 2014,Abstract#1882.
|
|
[19]BOURLIERE M,RABIEGA P,GANNE-CARRIE N,et al.HBsA g clearance after addition of 48 weeks of PEGIFN in HBeA g negative CHB patients on Nucleos(t)ide therapy with undetectable HBV DNA for at least one year:a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study:preliminary findings[C].AASLD 2014,Abstract#1863.
|
|
[20]LAMPERTICO P,BRUNETTO MR,CRAXI A,et al.Add-on PEGinterferon Alfa-2a significantly reduces HBsA g levels in HBeA g-negative,genotype D chronic hepatitis B patients fully suppressed on nucleot(s)ide analogues treatment:final results of the HERMES study[C].EASL 2016,Abstract#LBP 521.
|
|
[21]SPRINZL MF,GRAMBIHLER A,TEUBER G,et al.Add on interferon-alpha-2a for the treatment of HBeA g negative hepatitis B patients receiving effective nucleos(t)ide therapy:interim results of the prospective multicenter PADD-ON trial[C].EASL 2016,Abstract#LBP 517.
|
|
[22]NING Q,HAN M,SUN Y,et al.Switching from entecavir to PegI FN alfa-2a in patients with HBeA g-positive chronic hepatitis B:a randomised open-label trial(OSST trial)[J].J Hepatol,2014,61(4):777-784.
|
|
[23]SUN J,MA H,XIE Q,et al.Response-guided Peginterferon therapy in patients with HBeA g-positive chronic hepatitis B:a randomized controlled study[J].J Hepatol,2016,65(4):674-682.
|
|
[24]PENG H,WEI F,LIU JY,et al.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification:a meta-analysis[J].Hepatol Int,2015,9(4):543-557.
|
DownLoad: